Fund moves

Tango Therapeutics (TNGX): Deep Track Capital, LP added to its stake +1M shares

Deep Track Capital, LP added to its stake in Tango Therapeutics, per its Q4 2025 13F.

2.45M
Shares reported · +1M vs prior quarter
0.39%
Disclosed portfolio weight
$21.7M
Reported value
Holdings as of
Dec 31, 2025
Filed
Feb 13, 2026

What stands out in this filing

  • 1,454,562 shares in Q3 2025, 2,454,562 now (+68.7% in share count).
  • Reported at $21.7M, 0.39% of the portfolio value in this 13F filing.
  • 4 other tracked managers reported the same kind of change for Q4 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 2, 2026, the Board of Directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) increased the number of directors of the Company to eight (8).”
  2. Jan 7, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On January 7, 2026, Barbara Weber, M.D. notified the board of directors (the “Board”) of the Company of her retirement and resignation as President and Chief Executive Officer of the Company, in each case, effective as of January 8, 2026 (the “Effective Date”).”

What came next

  1. Mar 5, 2026Company filing · Form 8-K · ResultsReported its results
  2. Apr 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.”
  3. May 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Separation Agreement As previously announced, on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.”
  4. May 13, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.”
  5. Jun 9, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Tango Therapeutics

For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TNGX page.

How this filing works

Explore the data

Common questions

What does this filing report about Tango Therapeutics (TNGX) stock?

Deep Track Capital, LP added to its stake in Tango Therapeutics, per its Q4 2025 13F. Now 2.45M shares, $21.7M reported value, 0.39% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2025. Filed: Feb 13, 2026.

What stands out in this filing?

1,454,562 shares in Q3 2025, 2,454,562 now (+68.7% in share count). Reported at $21.7M, 0.39% of the portfolio value in this 13F filing. 4 other tracked managers reported the same kind of change for Q4 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Tango Therapeutics recently?

For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the TNGX page.

Does this mean TNGX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Tango Therapeutics

Everything OQRO holds on this company is on its TNGX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data